NasdaqGM:WVEPharmaceuticals
Wave Life Sciences (WVE) Q1 Revenue Surge Tests Bearish Profitability Concerns
Wave Life Sciences (WVE) has opened Q1 2026 with revenue of US$38.2 million and a basic EPS loss of US$0.13, compared with Q1 2025 revenue of US$9.2 million and a basic EPS loss of US$0.29. Over the same stretch, trailing twelve month revenue moved from US$104.9 million in Q1 2025 to US$71.8 million in Q1 2026, while trailing EPS shifted from a loss of US$0.77 to a loss of US$1.03, creating a mixed read on top line scale versus ongoing earnings pressure. For investors, the key question is...